A First-in-Human Randomized, Double-blind, Placebo-controlled, Fed-fasted, Gender, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OMT-28 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2018
Price : $35 *
At a glance
- Drugs OMT 28 (Primary)
- Indications Atrial fibrillation; Myocardial infarction
- Focus Adverse reactions; First in man
- Sponsors OMEICOS Therapeutics
- 26 Jul 2018 Status changed from recruiting to completed.
- 16 Mar 2017 Planned patient no is 92 as per NCT record. Kept higher no as per MR.
- 09 Mar 2017 New trial record